Skip to main content
GenMont logo

GenMont — Investor Relations & Filings

Ticker · 3164 ISIN · TW0003164000 TW Manufacturing
Open in API
Filings indexed 1,619 across all filing types
Latest filing 2014-11-10 Interim / Quarterly Rep…
Country TW Taiwan
Listing TW 3164

About GenMont

www.genmont.com.tw

GenMont Biotech Inc. specializes in the research, development, and manufacturing of functional probiotics and postbiotics. The company operates advanced fermentation and production platforms for concentrated fermented milk, lactic acid bacteria powders, and functional microorganism strains. Its product portfolio features patented probiotic solutions targeting diverse health areas, including immune modulation, metabolic health, dental hygiene, digestive function, weight management, and pet wellness. Key proprietary strains include L. paracasei 33 and GMNL-32. GenMont leverages its technology platforms and extensive patent portfolio to deliver scientifically-backed health supplements. Beyond its proprietary brands, the company provides original equipment manufacturing (OEM) services, supporting the global market with high-quality probiotic and postbiotic ingredients certified by international standards.

Recent filings

Filing Released Lang Actions
103年10月營業收入
Interim / Quarterly Report Classification · 85% confidence The document is a revenue summary report from a listed company, showing monthly and cumulative net operating revenue figures with percentage changes and explanatory notes. It is a brief financial data disclosure, typical of a periodic revenue update rather than a full financial report. The document length is short (787 characters), and it does not contain comprehensive financial statements or detailed analysis. It is not an announcement of a report publication but a direct data disclosure. This fits best with an Interim / Quarterly Report (IR) category, as it provides substantive financial data for a specific period (October of a given year) and cumulative year-to-date figures, which is characteristic of interim financial reporting. Q3 2014
2014-11-10 Chinese
103年11月變更登記
Share Issue/Capital Change Classification · 95% confidence The document is a brief disclosure of the company's capital structure details, including authorized capital, paid-in capital, and sources of capital changes. It does not contain financial statements, management discussion, or detailed financial results. The document length is short (796 characters) and it appears to be a regulatory announcement about capital information rather than a full report. There is no indication of a report being attached or published, nor is it a certification or voting result. The content fits best with a Share Issue/Capital Change announcement, as it details capital amounts and changes.
2014-11-03 Chinese
103年10月僑外投資持股
Major Shareholding Notification Classification · 95% confidence The document is a statistical table showing changes in shareholding by overseas and mainland China investors, specifically indicating a change due to a cash capital increase. It includes details on share counts before and after the change, and the total shares issued. The document is short (1059 characters) and is a regulatory disclosure of shareholding changes rather than a full financial report or announcement of a meeting or vote. It does not contain financial statements, management discussion, or audit information. It fits best as a Major Shareholding Notification (MRQ) because it reports changes in significant share ownership levels.
2014-10-23 Chinese
本公司103年現金增資收足股款暨增資基準日
Capital/Financing Update Classification · 95% confidence The document is a short announcement from a company (景岳生物科技股份有限公司) regarding the completion of a cash capital increase, specifying the number of new shares issued, the price per share, total amount raised, and the record date for the capital increase. It is dated 103/10/22 (Taiwan calendar year). The content is a factual update about a financing event, not a full financial report or detailed analysis. The document length is only 671 characters, indicating it is a brief announcement rather than a comprehensive report. This fits the definition of a Capital/Financing Update (CAP) as it relates to company fundraising and capital structure changes.
2014-10-22 Chinese
補充公告本公司現金增資全體董監事放棄認購股數達得認購股數 二分之一以上，並洽特定人認購事宜。
Share Issue/Capital Change Classification · 95% confidence The document is a disclosure from a listed company regarding the waiver of subscription rights by all directors and supervisors in a cash capital increase, and the subsequent subscription by specific persons. It details the number of shares waived and the reasons, indicating a capital structure change event. The document is short (858 characters) and focuses on share subscription and capital increase matters. This fits the category of a Share Issue/Capital Change announcement rather than a full financial report or other types of filings.
2014-10-21 Chinese
更正公告本公司現金增資全體董監事放棄認購股數達得認購股數 二分之一以上，並洽特定人認購事宜。
Capital/Financing Update Classification · 95% confidence The document is a short announcement (840 characters) from a listed company regarding the waiver of subscription rights by all directors and supervisors for a cash capital increase, and the arrangement to have specific persons subscribe instead. It includes details of the directors and supervisors who waived their subscription rights and mentions that further announcements will be made after the specific persons are confirmed. This is an update on a capital financing activity, specifically about share subscription and capital increase. It is not a full financial report, earnings release, or management discussion. It is not a report publication announcement or certification. Therefore, it fits best under Capital/Financing Update (CAP).
2014-10-17 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.